Get the Weekly Intelligence Brief — top committee picks every Sunday.
ARGX · NASDAQ · STOCK

argenx SE (ARGX) Stock Analysis

Healthcare Updated October 10, 2026
$825.04
52W $661.85 – $1072.75
59/100
$51.31B
29.6
-0.02
AI Committee Verdict
Buy
59/100
Conviction: Contested · 50% agreement · 6 analysts
+3.2%
-6.5%
0.50:1
Contested
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is ARGX Bullish or Bearish?

Bullish. Innellis AI committee rates argenx SE (ARGX) Buy with a composite score of 59/100 , based on 6 analysts with 50% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +15.95 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -4.05 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 165.2% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 22.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 165.2% YoY -- genuine top-line momentum — Growth
  • EPS growing 95.7% YoY — Growth
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
Bear Case
  • Price-to-book of 6.7x prices in significant intangible value — Value
  • RSI at 18 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Price trading below the lower Bollinger Band -- stretched to the downside — Technical
  • Bollinger bandwidth of 20.9% signals elevated volatility — Risk
  • News sentiment is negative (-0.20 across 44 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
59/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 38%
of 192 Healthcare peers
Value Analyst neutral
59 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 22.4% shows genuine earnings power backing the valuation
− Price-to-book of 6.7x prices in significant intangible value
Growth Analyst bullish
84 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 165.2% YoY -- genuine top-line momentum
Technical Analyst bearish
38 / 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 18 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
− Bollinger bandwidth of 20.9% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
51 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.20 across 44 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 59.0 to 59.0.

Analyst-level changes:
  • News Analyst: +1 bearish signal(s).
  • Risk Analyst: +1 bearish signal(s).
  • Technical Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
17.8
Oversold
MACD Histogram
-15.463
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$771.39
Resistance
$851.86
Bollinger %B
-0.11
Below Lower Band
Price vs Moving Averages
EMA 9
$897.53 Below
EMA 21
$934.27 Below
EMA 50
$942.22 Below
EMA 200
$867.89 Below

Fundamental Analysis

Valuation
57
Growth
88
Profitability
97
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 29.6×
P/B Ratio 6.03×
PEG Ratio 0.09
Dividend Yield 0.00%
52W High $1072.75
52W Low $661.85
Quality & Growth
ROE 1764.3%
ROA 1488.1%
Gross Margin 8994.2%
Operating Margin 2880.6%
Revenue Growth YoY —
Debt / Equity 0.01
AI Fundamental Assessment
P/E ratio of 29.6 (moderate relative to a 15-40x range); Price-to-book of 6.0x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 17.6%; Return on assets of 14.9%; Net margin of 32.9%; Gross margin of 89.9%; Current ratio of 5.12 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is positive (18.00); Most recent quarter beat estimates by 16.5%; 4 consecutive earnings beats; EPS growth accelerating (-31.2% -> +32.8% QoQ); Analyst estimates flat over recent quarters
Get the Full ARGX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime